Primary hepatic neuroendocrine tumours of liver- a rarity: Single centre analysis of 13 patients.
NETs of liver
Primary NETs of liver
Rare liver tumours
Journal
Annals of hepato-biliary-pancreatic surgery
ISSN: 2508-5859
Titre abrégé: Ann Hepatobiliary Pancreat Surg
Pays: Korea (South)
ID NLM: 101698342
Informations de publication
Date de publication:
Feb 2020
Feb 2020
Historique:
received:
23
10
2019
revised:
14
12
2019
accepted:
19
01
2020
entrez:
18
3
2020
pubmed:
18
3
2020
medline:
18
3
2020
Statut:
ppublish
Résumé
Primary hepatic neuroendocrine tumours (PHNETs) are a rarity and this rarity imparts management complexities. A retrospective analysis of prospectively maintained liver database from 2009 to 2018 was performed and patients with PHNETs were identified and studied for clinical, imaging and pathological features, surgical outcomes, disease free and overall survival. Thirteen patients of PHNET were identified following rigorous investigational protocols, which constituted 0.6% of all liver tumours (2095) in our series. The median age of patients was 50 years (14-65), with male to female ratio of 9:4. Eight patients (62%) underwent hepatic resections as primary treatment, while 5 (38%) patients received peptide receptor radiotherapy, trans-arterial chemotherapy, trans-arterial radiotherapy or a combination of these. In the surgical group at a median follow up of 36 months (range 5-114 months), 4 (50%) patients were alive without disease and disease free survival was 20 months. Median OS in surgical group was 47 months (40-53, 95% confidence interval) that was better but not statistically significant from that of non-surgical treatment group (36 months). PHNETs are rare tumours that require multidisciplinary treatment approach. Liver directed surgery centred management leads to better clinical outcomes in these selected patients.
Sections du résumé
BACKGROUNDS/AIMS
OBJECTIVE
Primary hepatic neuroendocrine tumours (PHNETs) are a rarity and this rarity imparts management complexities.
METHODS
METHODS
A retrospective analysis of prospectively maintained liver database from 2009 to 2018 was performed and patients with PHNETs were identified and studied for clinical, imaging and pathological features, surgical outcomes, disease free and overall survival.
RESULTS
RESULTS
Thirteen patients of PHNET were identified following rigorous investigational protocols, which constituted 0.6% of all liver tumours (2095) in our series. The median age of patients was 50 years (14-65), with male to female ratio of 9:4. Eight patients (62%) underwent hepatic resections as primary treatment, while 5 (38%) patients received peptide receptor radiotherapy, trans-arterial chemotherapy, trans-arterial radiotherapy or a combination of these. In the surgical group at a median follow up of 36 months (range 5-114 months), 4 (50%) patients were alive without disease and disease free survival was 20 months. Median OS in surgical group was 47 months (40-53, 95% confidence interval) that was better but not statistically significant from that of non-surgical treatment group (36 months).
CONCLUSIONS
CONCLUSIONS
PHNETs are rare tumours that require multidisciplinary treatment approach. Liver directed surgery centred management leads to better clinical outcomes in these selected patients.
Identifiants
pubmed: 32181424
doi: 10.14701/ahbps.2020.24.1.17
pmc: PMC7061040
doi:
Types de publication
Journal Article
Langues
eng
Pagination
17-23Informations de copyright
Copyright © 2020 by The Korean Association of Hepato-Biliary-Pancreatic Surgery.
Références
Oncol Lett. 2014 Apr;7(4):956-962
pubmed: 24944650
Indian J Pathol Microbiol. 2010 Oct-Dec;53(4):760-2
pubmed: 21045409
Ann Surg Oncol. 2003 Dec;10(10):1171-5
pubmed: 14654473
Lancet. 1998 Sep 5;352(9130):799-805
pubmed: 9737302
Acta Radiol. 2014 May;55(4):389-98
pubmed: 23928010
Hepatobiliary Pancreat Dis Int. 2010 Feb;9(1):44-8
pubmed: 20133228
Turk J Gastroenterol. 2012 Jun;23(3):272-8
pubmed: 22798119
J Gastroenterol Hepatol. 2002 Oct;17(10):1119-24
pubmed: 12201876
Endocrinol Metab Clin North Am. 2018 Sep;47(3):463-470
pubmed: 30098710
Cases J. 2009 Jan 27;2(1):90
pubmed: 19173727
Med Sci Monit. 2001 Jul-Aug;7(4):746-50
pubmed: 11433205
J Gastrointest Surg. 2008 Apr;12(4):725-30
pubmed: 18046612
J Gastroenterol Hepatol. 2012 Aug;27(8):1306-11
pubmed: 22414232
Asian Pac J Cancer Prev. 2014;15(6):2541-6
pubmed: 24761861
J Gastrointestin Liver Dis. 2011 Dec;20(4):439-42
pubmed: 22187713
Cancer. 1990 Mar 1;65(5):1211-8
pubmed: 2302669
Intern Med. 2005 Sep;44(9):958-62
pubmed: 16258211
Acta Pathol Jpn. 1993 Dec;43(12):783-9
pubmed: 8109257
Dig Surg. 2008;25(5):364-8
pubmed: 18984960
Abdom Imaging. 2004 Jan-Feb;29(1):77-81
pubmed: 15160757